A class of drugs called BACE1 inhibitors, originally designed to treat Alzheimer's disease, shows potential for the treatment of glioblastoma brain cancer.
According to researchers, targeting multiple angiogenesis pathways simultaneously could help overcome the resistance to anti-angiogenic treatment developed by glioblastoma brain cancer.
Researchers report on how exosomic miRNAs released within a tumor environment affect resistance to chemotherapy.
